Your browser doesn't support javascript.
loading
COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report.
Batista, Daniel Valente; Vieira, Carla Antoniana Ferreira de Almeida; Costa, Thomaz Alexandre; Lima, Eduardo Gomes.
Afiliação
  • Batista DV; Hospital Alemão Oswaldo Cruz, Intensive Care Unit, São Paulo, Brazil.
  • Vieira CAFA; University of Sao Paulo Heart Institute, São Paulo, Brazil.
  • Costa TA; Clinical Pharmacology Unit, Drug Research and Development Center (NPDM), Federal University of Ceará (UFC), Coronel Nunes de Melo #1000, Fortaleza, CE 60430-275 Brazil.
  • Lima EG; Clinical Pharmacology Unit, Drug Research and Development Center (NPDM), Federal University of Ceará (UFC), Coronel Nunes de Melo #1000, Fortaleza, CE 60430-275 Brazil.
Diabetol Int ; : 1-4, 2020 Oct 28.
Artigo em Inglês | MEDLINE | ID: mdl-33133998
ABSTRACT
Type 2 diabetes mellitus (DM) patients are at high risk for the development of severe COVID-19. Euglycemic diabetic ketoacidosis (eu-DKA) is a rare life-threatening complication associated with the use of SGLT2 inhibitor that may be unnoticed, particularly in a pandemic setting, due to the absence of significant hyperglycemia, delaying its treatment. In this report, we describe a case of a 56-year-old patient who presented an elevated anion gap metabolic acidosis during a SARS-CoV-2 infection and was diagnosed with SGLT2-associated euglycemic diabetic ketoacidosis. COVID-19 may increase patients' insulin demand, present gastrointestinal symptoms, and increase the production of ketone bodies. This situation can be worsened in susceptible diabetic patients on SLGT2 inhibitors, due to the persistent glycosuria, which can cause volume depletion. Recently some authors recommended that insulin-deficient patients or those using SGLT2 inhibitors should monitor for ketosis using available home testing kits in case of infections and should discontinue the medication in case of COVID-19. Given the increased use of this drug class in the management of type 2 DM patients due to its reduction of cardiovascular risk, we set out to emphasize the importance for the medical community to consider the possibility of eu-DKA on SARS-CoV-2-infected patients using SLGT2 inhibitors, so physicians can provide these patients with appropriate therapy promptly.
Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de estudo: Relato de casos / Fatores de risco Idioma: Inglês Revista: Diabetol Int Ano de publicação: 2020 Tipo de documento: Artigo País de afiliação: Brasil

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de estudo: Relato de casos / Fatores de risco Idioma: Inglês Revista: Diabetol Int Ano de publicação: 2020 Tipo de documento: Artigo País de afiliação: Brasil